Research programme: neurological disorders therapeutics - Avineuro/ChemDiv

Drug Profile

Research programme: neurological disorders therapeutics - Avineuro/ChemDiv

Alternative Names: AVN 0189; AVN 3085; AVN 3205; AVN-329; AVN-426

Latest Information Update: 12 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ChemDiv
  • Developer Avineuro Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neurological disorders

Most Recent Events

  • 12 Sep 2016 Research programme for Neurological disorder therapeutics is still in Preclinical development for Neurological disorders in USA (Avineuro Pharmaceuticals pipeline, September 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neurological-disorders in USA
  • 22 Nov 2008 ChemDiv and Avineuro Pharmaceuticals extend the term of their existing research and development collaboration covering multiple compounds for various Neurological disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top